These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21831734)

  • 61. Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors: Case series.
    Müller C; Kreissl MC; Klose S; Krause A; Keitel V; Venerito M
    Medicine (Baltimore); 2022 Jan; 101(4):e28610. PubMed ID: 35089197
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Role of chemotherapy in gastro-entero-pancreatic neuroendocrine tumors: the end of a story?
    Delaunoit T; Van den Eynde M; Borbath I; Demetter P; Demolin G; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Cutsem E; Van Hootegem P; Van Laethem JL; Verslype C; Hendlisz A
    Acta Gastroenterol Belg; 2009; 72(1):49-53. PubMed ID: 19402372
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Extended cycle streptozotocin/5-FU chemotherapy for maintenance therapy in pancreatic neuroendocrine tumors.
    Schrader J; Henes FO; Blaeker M; Zimmermann-Fraedrich K; Pace A; Perez D; Izbicki JR; Lohse AW; Benten D
    Endocrine; 2019 Aug; 65(2):460-467. PubMed ID: 31037707
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A phase II trial of streptozotocin and adriamycin in advanced APUD tumors.
    Frame J; Kelsen D; Kemeny N; Cheng E; Niedzwiecki D; Heelan R; Lippermann R
    Am J Clin Oncol; 1988 Aug; 11(4):490-5. PubMed ID: 2841843
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Major hyperghrelinemia in advanced well-differentiated neuroendocrine carcinomas: report of three cases.
    Walter T; Chardon L; Hervieu V; Cohen R; Chayvialle JA; Scoazec JY; Lombard-Bohas C
    Eur J Endocrinol; 2009 Oct; 161(4):639-45. PubMed ID: 19605542
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy.
    Lahner H; Mathew A; Klocker AL; Unger N; Theysohn J; Rekowski J; Jöckel KH; Theurer S; Schmid KW; Herrmann K; Führer D
    Endocrine; 2022 Jan; 75(1):293-302. PubMed ID: 34480724
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series.
    Naidoo J; O'Toole D; Kennedy MJ; Reynolds JV; O'Connor M; O'Byrne K
    Ir J Med Sci; 2012 Jun; 181(2):211-4. PubMed ID: 22048868
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors.
    Eriksson B; Skogseid B; Lundqvist G; Wide L; Wilander E; Oberg K
    Cancer; 1990 May; 65(9):1883-90. PubMed ID: 1695540
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors.
    Pavel ME; Baum U; Hahn EG; Hensen J
    Int J Gastrointest Cancer; 2005; 35(3):179-85. PubMed ID: 16110119
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Neuroendocrine pancreatic tumors and helpfulness of targeted therapies].
    Vaysse T; Coriat R; Perkins G; Dhooge M; Brezault C; Chaussade S
    Presse Med; 2013 Jun; 42(6 Pt 1):961-7. PubMed ID: 23009947
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A Systemic Inflammation Response Index Could be a Predictive Factor for mFOLFIRINOX in Metastatic Pancreatic Cancer.
    Pacheco-Barcia V; Mondéjar Solís R; France T; Asselah J; Donnay O; Zogopoulos G; Bouganim N; Guo K; Rogado J; Martin E; Alcindor T; Colomer R
    Pancreas; 2019; 48(5):e45-e47. PubMed ID: 31090669
    [No Abstract]   [Full Text] [Related]  

  • 72. [Well differentiated endocrine carcinomas of the pancreas].
    Čolović R; Grubor N; Micev M; Dugalić V; Stojakov D; Latinčić S; Čolović N; Jovanović M; Karapandžić V
    Srp Arh Celok Lek; 2011; 139(9-10):625-30. PubMed ID: 22069997
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Chemotherapy for carcinoma of the pancreas.
    Waddell WR
    Surgery; 1973 Sep; 74(3):420-9. PubMed ID: 4722709
    [No Abstract]   [Full Text] [Related]  

  • 74. Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study.
    Legoux JL; Lombard-Bohas C; Brixi H; Le Malicot K; Lecomte T; Dahan L; Ruszniewski P; Mahamat-Abakar A; Etienne PL; Caroli-Bosc FX; Dominguez S; Paule B; Terrebonne E; Michel P; Lepage C; Choukroun G;
    Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101572. PubMed ID: 33751987
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Selection of Chemotherapy in Advanced Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma.
    Weaver JMJ; Hubner RA; Valle JW; McNamara MG
    Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894318
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Squamous cell carcinoma of the pancreas.
    Al-Shehri A; Silverman S; King KM
    Curr Oncol; 2008 Dec; 15(6):293-7. PubMed ID: 19079631
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.
    Ito T; Okusaka T; Nishida T; Yamao K; Igarashi H; Morizane C; Kondo S; Mizuno N; Hara K; Sawaki A; Hashigaki S; Kimura N; Murakami M; Ohki E; Chao RC; Imamura M
    Invest New Drugs; 2019 Jun; 37(3):591. PubMed ID: 30903344
    [TBL] [Abstract][Full Text] [Related]  

  • 78. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
    Hentic O; Hammel P; Couvelard A; Rebours V; Zappa M; Palazzo M; Maire F; Goujon G; Gillet A; Lévy P; Ruszniewski P
    Endocr Relat Cancer; 2012 Dec; 19(6):751-7. PubMed ID: 22940375
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers.
    Bendell JC; Zakari A; Lang E; Waterhouse D; Flora D; Alguire K; McCleod M; Peacock N; Ruehlman P; Lane CM; Earwood C; Shih K
    Cancer Invest; 2016 May; 34(5):213-9. PubMed ID: 27127841
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Capecitabine, Oxaliplatin, Irinotecan, and Bevacizumab Combination Followed by Pazopanib Plus Capecitabine Maintenance for High-Grade Gastrointestinal Neuroendocrine Carcinomas.
    Alifieris CE; Griniatsos J; Delis SG; Nikolaou M; Avgoustou C; Panagiotidis MI; Souferi-Chronopoulou E; Trafalis DT
    Am J Clin Oncol; 2020 May; 43(5):305-310. PubMed ID: 32343515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.